parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in myonuclei	0.75
chemistry Open Targets	compounds already reach it: dantrolene sodium, dantrolene	1.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 435	0.79
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 12617

receipt 12626: RYR3 in dopamine neurons, braak

power: full sample +0.32 (p 0.201, n 18), 95% CI -0.18 to +0.68. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.33 (p 0.179, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.36 (p 0.148, n 18). could be the mix.
skeptic: leave-one-out range +0.22 to +0.42, sign flips 0; without severely affected donors +0.32 (p 0.201, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RYR3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12625: RYR3 in astrocytes, braak

power: full sample +0.42 (p 0.080, n 18), 95% CI -0.05 to +0.74. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.42 (p 0.080, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.44 (p 0.067, n 18). could be the mix.
skeptic: leave-one-out range +0.34 to +0.56, sign flips 0; without severely affected donors +0.42 (p 0.080, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RYR3 in astrocytes.

case closed: nothing better to follow up.

loading the receipts